BeyondSpring to Present at the Jefferies 2017 Healthcare Conference
June 02, 2017 16:32 ET
|
BeyondSpring, Inc.
NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies,...
BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017
May 08, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, May 08, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced...
BeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention
April 25, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, April 25, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017
March 22, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, March 22, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia
March 20, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo
March 14, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, March 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...